Earlier this year, in Marchand v. Barnhill, the Delaware Supreme Court underscored that boards that fail to establish oversight procedures for their company’s mission critical functions can be held liable for breach of their Caremark duties. In an October 1, 2019 decision in the Clovis Oncology Derivative Litigation, the Delaware Chancery Court provided further perspective on directors’ potential liability for breaches of the duty of oversight. The Chancery court held, citing Marchand,  that boards not only must be able to show that they have made good faith efforts to implement an oversight system, but that also that they monitor the system – particularly when a company operates in a highly regulated industry.  The Chancery Court’s October 1, 2019 decision in the Clovis Oncology Derivative Litigation can be found here.
Continue Reading Caremark Duties Include Duty Not Only to Establish Oversight Processes but Also to Monitor Them

sup ct 5ERISA plan fiduciaries have a continuing duty to monitor selected plan investments and to remove imprudent investment selections, according to the U.S. Supreme Court’s unanimous May 18, 2015 opinion in Tibble v. Edison International. Although the Court affirmed the fiduciary duty to monitor, it otherwise left the development of the duty’s contours to be delineated